ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ALK Molecular Glue Degrader TRI-611

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by TRIANA Biomedicines.

Furthest: phase 2, since Mar 11, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TRIANA Biomedicines11 open or runningphase 2since Mar 11, 2026Mar 11, 2026May 31, 2029phase 2 · NCT07491497

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2026First study: phase 2 study in ALK-positive NSCLCFirst studyNCT07491497 · 160 planned · United States, Australia, France and more

Ahead

  1. May 31, 2029Primary completion: phase 2 study in ALK-positive NSCLCNCT07491497

TargetBeta

ALK →read by rule
“An orally bioavailable, central nervous system (CNS) penetrant molecular glue degrader (MGD) of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), ”NCIt, by rule

Other programs on ALK

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
lorlatinibrulePfizerphase 420
gilteritinibruleAstellas Pharmaphase 320
ensartinibruleBetta Pharmaceuticalsphase 312
repotrectinibruleBristol-Myers Squibbphase 39
neladalkibGlaxoSmithKlinephase 32
Foritinib SuccinateFosun Pharmaphase 21
AQUA07Hoffmann-La Rochephase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07491497ALK-positive NSCLC · United States, Australia, France and more2RecruitingMay 31, 2029160

How it is read

Names in the registry

  • “TRI-611”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ALK Molecular Glue Degrader TRI-611 (TRIANA Biomedicines): development program | ClinicalTrials.gg